COMBINATION THERAPY OF A T CELL THERAPY AND AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR AND RELATED METHODS

Provided are methods, uses, and articles of manufacture of combination therapies involving immunotherapies and cell therapies, such as adoptive cell therapy, e.g. a T cell therapy, and the use of an inhibitor of an enhancer of zeste homolog 2 (EZH2), for treating subjects having or suspected of havi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CHANG, Henry, MOHAN, Adithi, OLSON, Nels Eric, NEWHALL, Katie, FILVAROFF, Ellen, FOX, Brian
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Provided are methods, uses, and articles of manufacture of combination therapies involving immunotherapies and cell therapies, such as adoptive cell therapy, e.g. a T cell therapy, and the use of an inhibitor of an enhancer of zeste homolog 2 (EZH2), for treating subjects having or suspected of having a cancer, and related methods, uses, and articles of manufacture. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs). L'invention concerne des méthodes, des utilisations, et des produits manufacturés de polythérapies impliquant des immunothérapies et thérapies cellulaires, telles que la thérapie cellulaire adoptive, par exemple une thérapie par lymphocytes T, et l'utilisation d'un inhibiteur d'une protéine-2 homologue de l'activateur de zeste (EZH2) pour traiter des sujets ayant ou suspectés d'avoir un cancer, et des méthodes, des utilisations, et des produits manufacturés associés. La thérapie par lymphocytes T comprend des cellules qui expriment des récepteurs recombinants tels que des récepteurs antigéniques chimériques (CAR).